JP2007514749A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514749A5
JP2007514749A5 JP2006545434A JP2006545434A JP2007514749A5 JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5 JP 2006545434 A JP2006545434 A JP 2006545434A JP 2006545434 A JP2006545434 A JP 2006545434A JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
toxoid
clostridium difficile
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006545434A
Other languages
English (en)
Japanese (ja)
Other versions
JP4904163B2 (ja
JP2007514749A (ja
Filing date
Publication date
Priority claimed from US10/737,270 external-priority patent/US6969520B2/en
Application filed filed Critical
Publication of JP2007514749A publication Critical patent/JP2007514749A/ja
Publication of JP2007514749A5 publication Critical patent/JP2007514749A5/ja
Application granted granted Critical
Publication of JP4904163B2 publication Critical patent/JP4904163B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006545434A 2003-12-16 2004-12-15 クロストリジウムディフィシル疾患に対する受動免疫感作 Expired - Fee Related JP4904163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/737,270 2003-12-16
US10/737,270 US6969520B2 (en) 1997-10-20 2003-12-16 Active immunization against clostridium difficile disease
PCT/US2004/042277 WO2005058353A1 (en) 2003-12-16 2004-12-15 Passive immunization against clostridium difficile disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011195944A Division JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作

Publications (3)

Publication Number Publication Date
JP2007514749A JP2007514749A (ja) 2007-06-07
JP2007514749A5 true JP2007514749A5 (https=) 2008-07-03
JP4904163B2 JP4904163B2 (ja) 2012-03-28

Family

ID=34700454

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006545434A Expired - Fee Related JP4904163B2 (ja) 2003-12-16 2004-12-15 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2011195944A Expired - Lifetime JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2015149504A Ceased JP2015205919A (ja) 2003-12-16 2015-07-29 クロストリジウムディフィシル疾患に対する受動免疫感作

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011195944A Expired - Lifetime JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2015149504A Ceased JP2015205919A (ja) 2003-12-16 2015-07-29 クロストリジウムディフィシル疾患に対する受動免疫感作

Country Status (7)

Country Link
US (6) US6969520B2 (https=)
EP (2) EP2394658A3 (https=)
JP (3) JP4904163B2 (https=)
AU (2) AU2004299105B8 (https=)
CA (1) CA2550108C (https=)
DK (1) DK1708743T3 (https=)
WO (1) WO2005058353A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB0306782D0 (en) * 2003-03-25 2003-04-30 Neutec Pharma Plc Treatment of infection due to clostridium difficile
CA2541753A1 (en) * 2003-07-10 2005-01-20 Michelle Alfa Combination therapy for gastroenteric diseases caused by microorganisms
NZ546569A (en) * 2003-10-24 2009-04-30 Univ Queensland Protein expression
WO2005106598A1 (ja) * 2004-04-28 2005-11-10 Canon Kabushiki Kaisha トナー
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2007072916A1 (ja) * 2005-12-22 2007-06-28 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 卵内接種用ワクチン
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
HUE037932T2 (hu) * 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
WO2010036826A1 (en) * 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for increasing toxin production
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
JP5408017B2 (ja) * 2009-06-05 2014-02-05 株式会社デンソー 蓄冷熱交換器
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
EP3821820B1 (en) 2011-01-19 2024-11-20 Access Closure, Inc. Apparatus and methods of manufacturing a sealing for a vascular puncture
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
HK1200463A1 (en) 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105142612A (zh) 2013-03-08 2015-12-09 奇普拉股份有限公司 用于直肠给药的药物组合物
EP2969012A4 (en) 2013-03-12 2016-09-14 Univ Yale COMPOSITIONS AND METHODS FOR IDENTIFYING SEQUENCEL ANTIBODY-BONDED MICROBES
KR20150133770A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
EP2970400A1 (en) * 2013-03-15 2016-01-20 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
EP2986316B1 (en) * 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
PL3003330T4 (pl) 2013-06-05 2019-03-29 Rebiotix, Inc. Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
EP3453396A1 (en) * 2014-08-28 2019-03-13 Yale University Compositions and methods for treating an inflammatory disease or disorder
HK1246196A1 (zh) * 2015-04-15 2018-09-07 Medimmune, Llc 用於治疗艰难梭菌(clostridium difficile)感染和相关疾病的方法
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN107921072A (zh) 2015-06-09 2018-04-17 雷柏奥提斯有限公司 微生物群恢复治疗（mrt）组合物和制造方法
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US968199A (en) * 1909-11-24 1910-08-23 Nathan Schwartz Muffler.
US4581020A (en) * 1983-07-18 1986-04-08 Trimedyne, Inc. Medication delivery device and system for percutaneous administration of medication
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
DE69223955T2 (de) 1991-04-22 1998-08-13 Massachusetts Health Research Institute, Inc. (Mhri), Boston, Mass. Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
CA2203504A1 (en) 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
CN1195993A (zh) 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
AU720567B2 (en) 1995-07-07 2000-06-08 Oravax, Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
BR9713312B1 (pt) * 1996-09-30 2009-08-11 preparado de vacina para uso veterinário útil para produzir imunidade ativa contra uma doença bacteriana ou protozoária.
US20050106157A1 (en) * 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) * 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US20040106590A1 (en) * 2002-08-29 2004-06-03 Barry Eisenstein Methods and reagents for treating infections of clostridium difficile and diseases associated therewith

Similar Documents

Publication Publication Date Title
JP2007514749A5 (https=)
JP2005524663A5 (https=)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2020033360A5 (https=)
JP2006501240A5 (https=)
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JP2015519329A5 (https=)
JP2009500443A5 (https=)
JP2002532432A5 (https=)
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2013503165A5 (https=)
JP2009515901A5 (https=)
MX2009010268A (es) Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
RU2010151660A (ru) Способы лечения множественной миеломы
OA12845A (en) Single dose azithromycin for treating respiratory infections.
Chambers et al. Management of skin and soft-tissue infection
JP2006514681A5 (https=)
JP2002530353A5 (https=)
JP2009500045A5 (https=)
Ramam et al. A two-step schedule for the treatment of actinomycotic mycetomas
JP2005507888A5 (https=)
CA2519789A1 (en) Aplidine for multiple myeloma treatment
Wilson Streptomycin in Non-tuberculous Infections